Bioconjugation specialist Innova Biosciences acquired by SYGNIS AG
Innova CEO and CSO Dr. Nick Gee becomes Chief Technical Officer of SYGNIS
28-Jun-2017 -
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.
Innova’s range of antibody and protein labeling products and services ideally complements SYGNIS’ ...
acquisitions
genomics
protein labeling
+1